A Massachusetts General Hospital (MGH)-led research team has identified an immune cell protein that is critical to setting off the body's initial response against viral infection.
The report that will be published in an upcoming issue of Nature Immunology and is receiving early online release describes finding that a protein called GEF-H1 is essential to the ability of macrophages – major contributors to the innate immune system – to respond to viral infections like influenza.
"The detection of viral genetic material inside an infected cell is critical to initiating the responses that signal the immune system to fight an infection and prevent its spread throughout the body," says Hans-Christian Reinecker, MD, of the Center for the Study of Inflammatory Bowel Disease in the MGH Gastrointestinal Unit, senior author of the report. "Our findings indicate that GEF-H1 may control immune responses against a wide variety of RNA and DNA viruses that pose a threat to human health."
The body's first line of defense against infection, the innate immune system rapidly responds to invading pathogens by mobilizing white blood cells, chemical factors called cytokines and antimicrobial peptides. When viruses invade cells, they often move towards the nucleus in order to replicate and sometimes to integrate their own genetic material into that of the host cell, traveling along structures called microtubules that cells use for internal protein transport. But how microtubule-based movement of viral components contributes to induction of the immune response has been unknown.
GEF-H1 is known to bind to microtubules, and previous research indicated that it has a role in immune recognition of bacteria. A series of experiments by Reinecker's team found that GEF-H1 is expressed in macrophages – key components of the innate immune system – and activated in response to viral RNA and that it controls the expression of beta interferon and other cytokines. Mice in which expression of GEF-H1 was knocked out were unable to mount an effective immune response to influenza A and to encephalomyocarditis, a virus that causes several types of infection in animals.
"The sensing of intracellular viral nucleic acids for induction of interferons is so important that many viruses, including influenza A, have evolved specific strategies to interfere with activation of the interferon defense system," says Reinecker, an associate professor of Medicine at Harvard Medical School. "We are hopeful that this discovery will allow the development of new strategies to curtail viral mechanisms that impede the immune responses to infections that are often associated with high mortality rates."
The co-lead authors of the Nature Immunology report are Hao-Sen Chiang, PhD, and Yun Zhao, MD, PhD, MGH Gastrointestinal Unit. Additional co-authors are Joo-Hye Song, PhD, Song Liu, MD, Megha Basavappa and Kate Jeffrey, PhD, MGH Gastrointestinal Unit; Ninghai Wang, MD, PhD, and Cox Terhorst, Beth Israel Deaconess Medical Center; and Arlene Sharpe, MD, PhD, Harvard Medical School. The study was supported by National Institutes of Health grants AI093588, DK-068181, DK-033506, 630 DK-043351 and DK-52510.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
Sue McGreevey | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences